GMP Peptide Manufacturer Retatrutide 2381089-83-2 10mg 12mg 25mg Purity 99.5%

Price $110.00 Compare
Min Order 1 KIT
Shipping From Zhejiang, China
Popularity 231 people viewed
Quantity
+-
 

Zhejiang Zhaobo Technology Co. Ltd.

VIP   Audited Supplier 2 years
Profile Certified by SGS/BV
LY-3437943
Nad+ Slows The Aging Process, Restores Neurologic
Non-Disposable
All
No
for Inj
Biofermentation
Weight Loss & Slimming
> 99.5% by HPLC
4731.33 (Free Base)
Ly3437943
Room Temperature in Continental Us
Sealed Storage, Away From Moisture
Type 2 Diabetes|Obesity|Overweight
ZPHC
Vials
5mg, 10mg, 12mg, 15mg, 20mg, 1g
China
Product Description

 

Product Description


Retatrutide is a 39 amino acid single peptide with triple agonist activity at the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). The backbone is conjugated to a C20 fatty diacid moiety at position 17.
Retatrutide has a Glucose-dependent insulinotropic polypeptide (GIP) peptide backbone, which then contains three non-coded amino acids. Aib2 (α-amino isobutyric acid) residues at positions 2 and 20 provide stability against Dipeptidyl Peptidase 4 (DPP4) cleavage and contribute to GIP activity. αMeL13 (α-methyl-L-leucine)at position 20 also contributes to GIP and glucagon activity.

Retatrutide can be used for the research of obesity obesity, diabetes, and fatty liver disease. It is a works in three ways: stimulating insulin release, suppressing appetite, and promoting fat breakdown.

Description

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT05929079Eli Lilly and Company
Type 2 Diabetes|Obesity|Overweight|Obstructive Sleep Apnea
July 11, 2023Phase 3
NCT04867785Eli Lilly and Company
Type 2 Diabetes
May 13, 2021Phase 2
NCT05882045Eli Lilly and Company
Obesity|Cardiovascular Diseases
May 30, 2023Phase 3
NCT05929066Eli Lilly and Company
Obesity|Overweight|Knee Pain Chronic|Knee Osteoarthritis|Obstructive Sleep Apnea
August 7, 2023Phase 3
NCT05916560Eli Lilly and Company
Healthy|Hepatic Insufficiency
July 13, 2023Phase 1
NCT05931367Eli Lilly and Company
Obesity|Overweight|Osteo Arthritis Knee
August 28, 2023Phase 3
NCT05611957Eli Lilly and Company
Healthy|Renal Insufficiency
November 16, 2022Phase 1
NCT05959096Eli Lilly and Company
Healthy
July 18, 2023Phase 1
NCT06003465Eli Lilly and Company
Healthy
August 29, 2023Phase 1
NCT04881760Eli Lilly and Company
Obesity|Overweight
May 20, 2021Phase 2
NCT03841630Eli Lilly and Company
Healthy
March 13, 2019Phase 1
NCT04823208Eli Lilly and Company
Diabetes Mellitus, Type 2
May 24, 2021Phase 1
NCT05936151Eli Lilly and Company
Overweight or Obesity|CKD|Type 2 Diabetes
July 20, 2023Phase 2
NCT05548231Eli Lilly and Company
Overweight|Obesity
October 24, 2022Phase 1
NCT04143802Eli Lilly and Company
Diabetes Mellitus, Type 2
December 18, 2019Phase 1
NCT05445232Eli Lilly and Company
Obesity
July 8, 2022Phase 1
 
Molecular Weight

4731.33 (free base)

Formula

C221H342N46O68.xC2HF3O2

Appearance

Solid

Color

White to off-white

Sequence

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

SMILES

[LY3437943 (TFA salt)]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder-80°C2 years
 -20°C1 year
 
Test reports

Retatrutide 3rd lab test reports

Services


Message Type
* Message Content
* Name  
* Phone
* Email
* CAPTCHA